Results 21 to 30 of about 211,280 (349)

The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factors

Frontiers in Immunology, 2022
Patients with COVID-19 often have hypoxemia, impaired lung function, and abnormal imaging manifestations in acute and convalescent stages. Alveolar inflammation, pulmonary vasculitis, and thromboembolism synergistically damage the blood-air barrier ...
Mengqi Xiang, Xiaoming Wu, Haijiao Jing, Langjiao Liu, Chunxu Wang, Yufeng Wang, Valerie A. Novakovic, Jialan Shi, Jialan Shi, Jialan Shi   +9 more
doaj   +1 more source

Bridging therapy according to new clinical guidelines: A review

Consilium Medicum, 2022
In modern world it is really important to know how to manage patients taking anticoagulant or antiplatelet therapy. There is an increasing number of patients, who have gone through PCI or any other cardiac intervention and who also need another surgery ...
Tatiana A. Pavlenko, Anastasiya Yu. Lebedeva, Denis N. Protsenko   +2 more
doaj   +1 more source

Antiplatelet drugs [PDF]

British Journal of Pharmacology, 2006
British Journal of Pharmacology (2006) 147, S241–S251.
Gustav, Born, Carlo, Patrono
openaire   +2 more sources

Percutaneous coronary intervention with drug‐coated balloon‐only strategy combined with single antiplatelet treatment in patients at high bleeding risk: Single center experience of a novel concept

Catheterization and cardiovascular interventions, 2023
At least 1 month of dual antiplatelet therapy is required after coronary stenting. The aim of this all‐comers retrospective registry study was to assess the efficacy and safety of percutaneous coronary intervention (PCI) using drug‐coated balloon (DCB ...
Alma Räsänen, J. Kärkkäinen, Antti Eranti, Jaakko Eränen, T. Rissanen   +4 more
semanticscholar   +1 more source

Sclerobanding in the treatment of second and third degree hemorrhoidal disease in high risk patients on antiplatelet/anticoagulant therapy without suspension: a pilot study

Frontiers in Surgery, 2023
IntroductionAround 20% of population in western countries is under anticoagulant treatment. However, there is paucity of evidence about the treatment of HD in patients under anticoagulant/antiplatelet therapy, although both suspension and continuation in
Francesco Pata, Francesco Pata, Luigi M. Bracchitta, Bruno Nardo, Gaetano Gallo, Giancarlo D’Ambrosio, Salvatore Bracchitta   +6 more
doaj   +1 more source

Dual Antiplatelet Therapy: A Concise Review for Clinicians

Life, 2023
Dual antiplatelet therapy (DAPT) combines two antiplatelet agents to decrease the risk of thrombotic complications associated with atherosclerotic cardiovascular diseases. Emerging data about the duration of DAPT is being published continuously.
H. H. Virk, Johao Escobar, Mario Rodriguez, E. Bates, U. Khalid, H. Jneid, Y. Birnbaum, Glenn N. Levine, Sidney C. Smith, C. Krittanawong   +9 more
semanticscholar   +1 more source

Sex differences in antiplatelet therapy: state-of-the art

Platelets, 2023
Antiplatelet therapy is a cornerstone of secondary prevention of cardiovascular diseases (CVDs). However, current guidelines are based on data derived primarily from men, as women are generally underrepresented in trials.
A. Gąsecka, J. Zimodro, Y. Appelman
semanticscholar   +1 more source

Antiplatelet therapy after percutaneous coronary intervention.

EuroIntervention, 2022
Antiplatelet therapy is key to reducing local thrombotic complications and systemic ischaemic events among patients undergoing percutaneous coronary interventions (PCI), but it is inevitably associated with increased bleeding.
D. Angiolillo, M. Galli, J. Collet, A. Kastrati, M. O’Donoghue   +4 more
semanticscholar   +1 more source

Outcomes in Antiplatelet‐Associated Intracerebral Hemorrhage in the TICH‐2 Randomized Controlled Trial

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2021
Background Antiplatelet therapy increases the risk of hematoma expansion in intracerebral hemorrhage (ICH) while the effect on functional outcome is uncertain.
Z. Law, Michael Desborough, I. Roberts, R. Al-Shahi Salman, T. England, D. Werring, Thompson G. Robinson, K. Krishnan, R. Dineen, A. Laska, N. Peters, J. Egea-Guerrero, M. Karliński, Hanne Christensen, C. Roffe, D. Bereczki, S. Ozturk, Jegan Thanabalan, R. Collins, M. Beridze, P. Bath, N. Sprigg   +21 more
semanticscholar   +1 more source

Antiplatelet Use in Ischemic Stroke

The Annals of Pharmacotherapy, 2022
Objective: A literature review of antiplatelet agents for primary and secondary stroke prevention, including mechanism of action, cost, and reasons for lack of benefit.
Marharyta Kamarova, S. Baig, Hamish Patel, K. Monks, M. Wasay, Ali N. Ali, J. Redgrave, A. Majid, S. Bell   +8 more
semanticscholar   +1 more source